Testing EVO756 to prevent migraines in adults
Part of Brain & nervous system clinical trials.
This study tests a new medication called EVO756 to help prevent migraines in adults who haven't had success with other preventive treatments. Researchers want to see if this new drug can reduce how often migraines happen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have been diagnosed with migraines (with or without aura, a visual warning sign)
- You have tried at least one other migraine preventive medication that didn't work well enough for you
- You are not currently taking any migraine preventive medication
- You can clearly tell the difference between your migraines and other types of headaches
- You don't have other serious medical conditions, heart problems, or psychiatric conditions that would make the study unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, MEDI0618, against a placebo for people with episodic migraine. The goal is to see if MEDI0618 is safe and effective at reducing migraine days.
This trial tests whether a computer algorithm can help pick the best migraine prevention medicine for you. You'll try one of several common preventives and track your headaches.
This study tests new ways to monitor how well preventive migraine treatments are working. It is for people with chronic migraine who may be starting or already using preventive medications.
This study tests a new inhaled powder form of a migraine medication called dihydroergotamine (DHE) to see if it safely and effectively stops migraine attacks. If you have frequent migraines, this trial might offer you a new treatment option to try.
This trial tests if eptinezumab can stop a migraine attack that is already happening. It may help people who get migraines often and are already part of the TACHIS study.
This trial studies eptinezumab, a migraine treatment, in children and teens ages 6 to 17 who already completed an earlier migraine study. It mainly helps doctors learn whether the treatment can be continued safely and effectively over time.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.